Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Clinical trial NCT06440993 · RECRUITING

Trial details

NCT number: NCT06440993
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Extrahepatic Cholangiocarcinoma Unresectable Perihilar or Ductal CCA

Start date: 2024-08-23
Primary completion: 2027-01-01
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.